National Cancer Registration Dataset
Cancer researchers investigate why smouldering myeloma progresses
Around 6,500 people are diagnosed with myeloma in the UK each year
AstraZenca’s Etcamah combination therapy given FDA Accelerated Approval for breast cancer
The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression
AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab approved in EU as first-line treatment for breast cancer
This is the first new regimen in more than a decade for first-line treatment for this type of breast cancer
Gilead’s Trodelvy approved by EC as first-line treatment for metastatic triple-negative breast cancer
TNBC is the most aggressive type of breast cancer and has historically been difficult to treat
Novartis agrees on potential $3bn deal to buy Synnovations’s breast cancer treatment
The oral drug is currently being evaluated for breast cancer and other advanced solid tumours in a phase 1/2 study
AstraZeneca and Daiichi Sankyo’s Datroway given FDA Priority Review for breast cancer treatment
Approximately 70% of metastatic triple-negative breast cancer patients are ineligible for immunotherapy, creating an unmet medical need
Gilead’s Trodelvy plus Keytruda shows positive results in metastatic breast cancer
The combination treatment showed a 35% reduction in the risk of disease progression
Lilly announces new study data on Inluriyo in metastatic breast cancer
The five-year survival rate for metastatic breast cancer is 30%
Gilead reports Trodelvy breast cancer trial missed primary survival endpoint
The drug treatment is being evaluated in several ongoing phase 3 trials
Lilly reports survival benefit with Verzenio in high-risk early breast cancer
The findings are based on Lilly’s phase 3 monarchE trial
Roche’s Itovebi granted EC approval to treat advanced breast cancer patients
Hormone receptor-positive breast cancer accounts for around 70% of all breast cancer cases
Researchers uncover promising treatment approach for inherited breast cancer
The study evaluated chemotherapy followed by a targeted cancer drug in patients before surgery